obesity therapy (BEXEL Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameobesity therapy (BEXEL Pharmaceuticals)
Drug Alias Nameobesity therapy (BEXEL Pharmaceuticals (Orchid/BEXEL Biotechnology))BLX-1028
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitorsIL-6 receptor antagonistsOrexin receptor agonists +[4] 
TargetsOrexin receptorIL-6 receptorTumor necrosis factor α +[4] 
Therapy Area/IndicationsObesityArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBEXEL Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBEXEL Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsObesityArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A